A Phase 3 Multicentre Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
A Phase 3 Multicentre Open-label Study of Brigatinib (AP26113) versus Crizotinib in
ALK-positive Advanced Lung Cancer Patients
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society